Open Access

Optimising oral anticoagulation for atrial fibrillation patients undergoing cardiac interventions in 2021: From evidence to practice

Event: ESC Congress 2021 - The Digital Experience
Topic: Atrial Fibrillation (AF)
Session type: Satellite Symposium
Sponsored by Bristol Myers Squibb and Pfizer
Date: 28 August 2021
Time: 13:00 - 13:45

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

4 presentations in this session

Welcome: The shifting risk/benefit balance of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation and cardiac interventions.

Speaker: Professor I. Van Gelder (Groningen, NL)

Building the evidence base for cardiac interventions in non-valvular atrial fibrillation.

Speaker: Professor R. Lopes (Durham, US)

Antithrombotic therapy in patients with transcatheter aortic valve implantation: Balancing risks with benefits.

Speaker: Professor J. ten Berg (Nieuwegein, NL)

Panel Q&A.


3 speakers from this session

Professor Isabelle C Van Gelder

University Medical Center Groningen, Groningen (Netherlands (The))
39 presentations

Professor Renato Lopes

Duke University Medical Center, Duke Clinical Research Institute, Durham (United States of America)
20 presentations
0 follower

Professor Jurrien M ten Berg

St Antonius Hospital, Nieuwegein (Netherlands (The))
16 presentations
0 follower

Related content

ESC Premium Access

Heart failure with preserved ejection fraction: are there new options?

4 December 2021

ESC Premium Access

Personalized Approaches to antiplatelet treatment in ACS-PCI patients

3 December 2021

ESC Premium Access

Current controversies in antithrombotic therapy

3 December 2021

This platform is supported by

logo Novo Nordisk